Aon Chairman Lester Knight Buys 20,000 Shares for $6.5 Million. What Does This Mean for Investors?

Mark Lappe, the founder and CEO of Inhibrx Biosciences, purchased 25,000 shares of the company on September 8, 2026. The transaction was valued at $2.6 million based on the weighted average purchase price of $105.82 per share. Upon closer examination of the market close on the same day, the value of those shares reached $114.34 each.

Inhibrx Biosciences is a clinical-stage biopharmaceutical company with a market capitalization of $1.40 billion. The firm distinguishes itself through its proprietary modular protein engineering platforms, which enable the development of novel biologic therapeutics. This unique technology allows for the optimization of therapeutic valency and agonist function, giving the company a competitive edge in the market. Inhibrx's clinical pipeline is focused on advancing its therapeutics toward potential regulatory milestones.

Despite being a pre-revenue clinical-stage company, Inhibrx's financial standing is reflective of the typical dynamics of biotechnology development-stage firms. The company's operating losses are balanced by the confidence and support of its investors, who believe in the potential of its platform technology and clinical pipeline. Lappe's recent share purchase appears to further bolster this confidence, signaling his belief in the company's long-term prospects.